Positive Canadian Reimbursement for LEQEMBI Adds Incremental Support to Biogen's Alzheimer's Thesis

What happened

Canada's Drug Agency issued a final positive recommendation for public reimbursement of LEQEMBI (lecanemab) for early Alzheimer's disease, marking another step in expanding market access. Biogen shares economics through its Alzheimer's collaboration with Eisai, recording 50% of product revenue net of costs, so this decision incrementally improves the commercial outlook. However, the master report already highlights that LEQEMBI collaboration revenue remains small at $59.5 million in Q1 2026, and reimbursement was one of several barriers to uptake. The larger catalysts for Biogen remain the July 29 Q2 results with Apellis-inclusive guidance and the August 24 FDA decision on subcutaneous LEQEMBI initiation. While positive, this news alone does not de-risk the core transition story or change the WAIT rating.

Implication

For investors, this news adds marginal support to the Alzheimer's franchise but does not address the key uncertainties that govern Biogen's valuation. The company still needs to prove that Apellis integration can deliver 2027 EPS accretion and that subcutaneous LEQEMBI approval can reduce site-of-care friction in the U.S. Canadian reimbursement may help volume but its financial impact is likely limited compared to U.S. dynamics. The master report's base case assigns a 45% probability to a $215 implied value, and this development is consistent with that scenario but not enough to shift probabilities. Until the July Q2 report and August FDA decision provide harder evidence, the stock remains in the WAIT range between the attractive entry of $185 and the trim level of $225. Therefore, investors should treat this news as incremental and await more definitive catalysts.

Thesis delta

The news does not materially change the investment thesis. The original thesis emphasized the need for July Q2 guidance and August SC approval; this news is a positive but external to those catalysts. Consequently, we maintain the WAIT rating and conviction of 4.0, with no change to price targets or scenarios.